Comparison 4. EVS versus octreotide.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Failure, rebleeding, mortality, adverse events	10		Risk Difference (M‐H, Random, 95% CI)	Subtotals only
1.1 Failure to control bleeding	10	1128	Risk Difference (M‐H, Random, 95% CI)	‐0.01 [‐0.07, 0.04]
1.2 Five‐day failure rate	2	132	Risk Difference (M‐H, Random, 95% CI)	‐0.14 [‐0.30, 0.03]
1.3 two to five‐day failure	4	341	Risk Difference (M‐H, Random, 95% CI)	‐0.05 [‐0.14, 0.04]
1.4 Rebleeding	9	1064	Risk Difference (M‐H, Random, 95% CI)	0.02 [‐0.03, 0.08]
1.5 Rebleeding before other elective treatments	5	486	Risk Difference (M‐H, Random, 95% CI)	‐0.01 [‐0.07, 0.05]
1.6 Mortality	10	1128	Risk Difference (M‐H, Random, 95% CI)	‐0.01 [‐0.06, 0.04]
1.7 Mortality before other elective treatments	5	531	Risk Difference (M‐H, Random, 95% CI)	‐0.00 [‐0.05, 0.04]
1.8 Adverse events	6	529	Risk Difference (M‐H, Random, 95% CI)	0.06 [‐0.03, 0.15]
2 Transfusions	5	391	Mean Difference (IV, Random, 95% CI)	‐0.20 [‐0.60, 0.20]